AbbVie touts promising PhIII data for Orilissa as execs line up their second pitch and rivals lay in wait
Researchers for AbbVie have detailed their data from a pair of Phase III uterine fibroid studies for Orilissa which they expect will push them to their second big OK for a drug widely viewed as a blockbuster-in-waiting.
Already approved for endometriosis, their drug at 300 mg twice daily easily outpaced a placebo in treating uterine fibroids, with a 68.5% and a 76.2% clinical response on the primary endpoint for reduced heavy menstrual bleeding. The placebo arms hit 8.7% and 10.1% respectively, offering a sharp and satisfying contrast for the AbbVie drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.